In Vivo Metabolism of Aristolochic Acid I and II in Rats Is Influenced by Their Coexposure
- 7 September 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in Chemical Research in Toxicology
- Vol. 33 (11) , 2804-2818
Abstract
The plant extract aristolochic acid (AA), containing aristolochic acid I (AAI) and II (AAII) as major components, causes aristolochic acid nephropathy and Balkan endemic nephropathy, unique renal diseases associated with upper urothelial cancer. Differences in the metabolic activation and detoxification of AAI and AAII and their effects on the metabolism of AAI/AAII mixture in the plant extract might be of great importance for an individual’s susceptibility in the development of AA-mediated nephropathies and malignancies. Here, we investigated in vivo metabolism of AAI and AAII after i.p. administration to Wistar rats as individual compounds and as AAI/AAII mixture using high performance liquid chromatography/electrospray ionization mass spectrometry. Experimental findings were supported by theoretical calculations using density functional theory. We found that exposure to AAI/AAII mixture affected the generation of their oxidative and reductive metabolites formed during Phase I biotransformation and excreted in rat urine. Several Phase II metabolites of AAI and AAII found in the urine of exposed rats were also analysed. Our results indicate that AAI is more efficiently metabolised in rats in vivo than AAII. Whereas AAI is predominantly oxidised during in vivo metabolism, its reduction is the minor metabolic pathway. In contrast, AAII is mainly metabolised by reduction. The oxidative reaction only occurs if aristolactam II, the major reductive metabolite of AAII, is enzymatically hydroxylated, forming aristolactam Ia. In AAI/AAII mixture, the metabolism of AAI and AAII is influenced by the presence of both AAs. For instance, the reductive metabolism of AAI is increased in the presence of AAII while the presence of AAI decreased the reductive metabolism of AAII. These results suggest that increased bioactivation of AAI in the presence of AAII also leads to increased AAI genotoxicity which may critically impact on AAI-mediated carcinogenesis. Future studies are needed to explain the underlying mechanism(s) for this phenomenon.Keywords
Funding Information
- Grantov? Agentura Cesk? Republiky (18-10251S)
This publication has 70 references indexed in Scilit:
- Aristolochic acid nephropathy: Harbinger of a global iatrogenic diseaseEnvironmental and Molecular Mutagenesis, 2012
- Evidence of exposure to aristolochic acid in patients with urothelial cancer from a Balkan endemic nephropathy region of RomaniaEnvironmental and Molecular Mutagenesis, 2012
- Local uses of Aristolochia species and content of nephrotoxic aristolochic acid 1 and 2—A global assessment based on bibliographic sourcesJournal of Ethnopharmacology, 2009
- Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathyMutation Research - Reviews in Mutation Research, 2008
- Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancerCarcinogenesis, 2007
- DNA adduct formation and mutation induction by aristolochic acid in rat kidney and liverMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2006
- Aristolochic acid as a probable human cancer hazard in herbal remedies: a reviewMutagenesis, 2002
- Mutagenicity of aristolochic acid in the lambda/lacZ transgenic mouse (Muta™Mouse)Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2002
- Urothelial Carcinoma Associated with the Use of a Chinese Herb (Aristolochia fangchi)New England Journal of Medicine, 2000
- Mutagenicity of the two main components of commercially available carcinogenic aristolochic acid in Salmonella typhimuriumCancer Letters, 1984